Hyperphosphatemia is a common and serious complication in patients receiving dialysis, contributing to vascular calcification, cardiovascular disease, secondary hyperparathyroidism, and increased mortality risk. Despite guideline-recommended strategies such as dietary modification, dialysis optimization, and phosphate binders, many patients continue to struggle to achieve target phosphorus levels due to high pill burden, treatment-related adverse effects, and challenges sustaining dietary changes.
Emerging therapies, including tenapanor and its novel mechanism of action, are reshaping the hyperphosphatemia treatment landscape and creating opportunities for a more patient-centered approach to care. Explore this clinical bulletin and podcast episode to learn practical strategies for integrating updated treatment approaches into dialysis practice.
Phosphorus in Phocus: Expanding the Hyperphosphatemia Toolkit in Dialysis